GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » GeneDx Holdings Corp (NAS:WGS) » Definitions » Capex-to-Operating-Income

GeneDx Holdings (GeneDx Holdings) Capex-to-Operating-Income : 0.00 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is GeneDx Holdings Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

GeneDx Holdings's Capital Expenditure for the three months ended in Dec. 2023 was $-2.38 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-25.64 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


GeneDx Holdings Capex-to-Operating-Income Historical Data

The historical data trend for GeneDx Holdings's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GeneDx Holdings Capex-to-Operating-Income Chart

GeneDx Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
- - - - -

GeneDx Holdings Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of GeneDx Holdings's Capex-to-Operating-Income

For the Health Information Services subindustry, GeneDx Holdings's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GeneDx Holdings's Capex-to-Operating-Income Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, GeneDx Holdings's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where GeneDx Holdings's Capex-to-Operating-Income falls into.



GeneDx Holdings Capex-to-Operating-Income Calculation

GeneDx Holdings's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-5.711) / -170.194
=N/A

GeneDx Holdings's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-2.376) / -25.643
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GeneDx Holdings  (NAS:WGS) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


GeneDx Holdings Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of GeneDx Holdings's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


GeneDx Holdings (GeneDx Holdings) Business Description

Traded in Other Exchanges
N/A
Address
333 Ludlow Street, North Tower, 6th Floor, Stamford, CT, USA, 06902
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets. It has two segments GeneDx and Legacy Sema4 diagnostics.
Executives
Kareem Saad officer: Chief Business Officer C/O SEMA4 HOLDINGS CORP, 333 LUDLOW STREET, NORTH TOWER, 8TH FL., STAMFORD CT 06902
Katherine Stueland director, officer: Chief Executive Officer 458 BRANNAN STREET, SAN FRANCISCO CA 94107
Kevin Feeley officer: Chief Financial Officer C/O SEMA4 HOLDINGS CORP, 333 LUDLOW STREET, NORTH TOWER, 8TH FL., STAMFORD CT 06902
Jason Ryan director C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Keith A. Meister director, 10 percent owner C/O ICAHN CAPITAL LP, 767 FIFTH AVENUE, SUITE 4700, NEW YORK NY 10153
Pfenniger Richard C Jr director 4400 BISCAYNE BLVD., MIAMI FL 33137
Karen Ann White officer: Chief People Officer C/O SEMA4 HOLDINGS CORP, 333 LUDLOW STREET, NORTH TOWER, 8TH FL., STAMFORD CT 06902
Casdin Partners Fo1-msv, Lp director, 10 percent owner C/O CASDIN PARTNERS GP, LLC, 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Partners Master Fund, L.p. director, 10 percent owner WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Eli Casdin director, 10 percent owner 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Capital, Llc director, 10 percent owner 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Partners Gp, Llc director, 10 percent owner 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Icahn School Of Medicine At Mount Sinai 10 percent owner 1 GUSTAVE L. LEVY PLACE, NEW YORK NY 10029
Corvex Management Lp director, 10 percent owner 667 MADISON AVENUE, NEW YORK NY 10065
Opko Health, Inc. 10 percent owner 4400 BISCAYNE BLVD., MIAMI FL 33137